摘要
多发性骨髓瘤(MM)是一种浆细胞恶性肿瘤,其特征是骨髓中浆细胞克隆性增殖,分泌单克隆免疫球蛋白或其片段(M蛋白),同时伴有广泛的溶骨病变及贫血、感染、肾功能损害等临床表现。硼替佐米是一种新型的蛋白酶体抑制剂,通过全新机制达到抗骨髓瘤作用。临床上硼替佐米单药及同其他常规化疗药物组成的联合方案对初治、复发/难治的MM患者均取得了良好的疗效。全文就硼替佐米治疗多发性骨髓瘤的临床进展作一综述。
Multiple myeloma is a plasma cell malignancy,characterized by clonal expansion of plasma cells in bone marrow,and monoclonal immunoglobulin or the fragment （M protein） produced by plasma cells,together with a wide range of dissolved bone lesions and clinical manifestations such as anemia,infection,impaired renal function. Bortezomib is a new type of proteasome inhibitors,which can fight against multiple myeloma through new mechanism. Bortezomib,as a single agent or being combined with other conventional chemotherapy agent,has positive therapeutic effect on patients with newly diagnosed or relapsed/refractory multiple myeloma. In this article,the clinical application of bortezomib to the treatment of multiple myeloma is reviewed.
出处
《中国肿瘤》
CAS
2014年第8期674-679,共6页
China Cancer
